{"filings":[{"id":1527000,"accession_number":"0001104659-26-081806","cik":1555279,"company_name":"908 Devices Inc.","ticker":"MASS","form_type":"8-K","filed_at":"2026-07-08T20:30:11+00:00","items":["8.01"],"status":"ready","headline":"908 Devices issues 3.2M shares to satisfy RedWave earnout; revenue threshold of $37M met","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued 3,213,583 shares of common stock as earnout consideration under the RedWave acquisition.","Earnout contingent on RedWave product/service revenue exceeding $37M over two years ending April 30, 2026.","Obligation satisfied in full, indicating the revenue threshold was met or exceeded.","Shares issued to CAM3 HoldCo, LLC for the benefit of beneficial sellers from the April 2024 purchase agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":331814522.81249994,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1027837,"accession_number":"0001104659-26-073487","cik":1555279,"company_name":"908 Devices Inc.","ticker":"MASS","form_type":"8-K","filed_at":"2026-06-12T20:20:09+00:00","items":["5.07"],"status":"ready","headline":"908 Devices shareholders elect directors, ratify auditor, approve exec comp at 2026 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board elected Class III directors Keith Crandell (23.99M for), Christopher Brown (24.12M), Kevin Hrusovsky (21.16M).","PricewaterhouseCoopers LLP ratified as independent auditor for FY2026 with 28.65M for, 5,575 against.","Say-on-pay advisory proposal approved with 21.19M for, 2.75M against (87% support).","Stockholders voted for an annual say-on-pay frequency; board adopted one-year cycle."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":331814522.81249994,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":93605,"accession_number":"0001104659-26-055912","cik":1555279,"company_name":"908 Devices Inc.","ticker":"MASS","form_type":"8-K","filed_at":"2026-05-06T23:59:59+00:00","items":["1.01","2.01","2.02","3.02","7.01","9.01"],"status":"ready","headline":"908 Devices Q1 rev +14% to $13.4M, raises FY26 outlook; buys NIRLAB for $15M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 revenue $13.4M (+14% YoY); recurring revenue $4.0M (30% of total); gross margin 51%, adj. 57%.","Net loss from cont. ops $12.0M; adj. EBITDA loss $2.5M vs $4.6M loss a year ago; cash $111.7M, no debt.","FY2026 revenue guidance raised to $67-70M (19-25% growth); installed base 3,903 devices (+23% YoY).","Completed acquisition of NIRLAB AG for $15M ($13M cash + $2M stock) plus up to $8M earn-out in stock.","NIRLAB adds NIR spectroscopy for narcotics; over 1M analyses; expands international and subscription revenue."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.32,"consensus_revenue_estimate":null,"consensus_revenue_actual":13381000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":331814522.81249994,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105374,"accession_number":"0001104659-26-022548","cik":1555279,"company_name":"908 Devices Inc.","ticker":"MASS","form_type":"8-K","filed_at":"2026-03-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"908 Devices Q4 rev $17.4M (+21% YoY); positive adj. EBITDA; FY2026 guide $64.5-67.5M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $17.4M (up 21% YoY); full-year revenue $56.2M (up 18% YoY).","Q4 GAAP net income from cont. ops $4.4M vs. loss $16.0M a year ago.","Achieved positive Adjusted EBITDA of $0.7M in Q4; FY2025 Adj. EBITDA loss $9.6M.","FY2026 revenue guidance $64.5M-$67.5M (15%-20% growth vs FY2025).","Cash and marketable securities $113.0M at Dec 31, 2025; no debt."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.72,"calibrated_materiality_score":0.72,"market_cap_usd":331814522.81249994,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105373,"accession_number":"0001104659-26-004798","cik":1555279,"company_name":"908 Devices Inc.","ticker":"MASS","form_type":"8-K","filed_at":"2026-01-20T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"908 Devices Q4 revenue $17.2M (+20% YoY); FY2025 ~$56M (+17%), positive Adj. EBITDA in Q4","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2025 revenue ~$17.2M versus $14.3M in Q4 2024, growth of ~20%.","FY2025 revenue ~$56.0M, up ~17% from $47.7M in FY2024, at high end of guidance.","Achieved positive Adjusted EBITDA in the fourth quarter, meeting a key goal.","Strength from U.S. state/local channel, ramping VipIR international sales, and federal/defense customers.","CEO cites macro tailwinds: increased fentanyl/opioid crisis funding and rising global defense budgets."],"consensus_eps_estimate":null,"consensus_eps_actual":0.54,"consensus_revenue_estimate":null,"consensus_revenue_actual":56197000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":331814522.81249994,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121659,"accession_number":"0001104659-25-108811","cik":1555279,"company_name":"908 Devices Inc.","ticker":"MASS","form_type":"8-K","filed_at":"2025-11-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"908 Devices Q3 revenue down 4% YoY to $14M, but 9-month revenue up 16%; reiterates FY25 guidance of $54-56M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 revenue of $14.0M, down 4% YoY; first nine months revenue up 16% to $38.8M; installed base grew 27% YoY to 3,512 devices.","Adjusted EBITDA loss improved 53% QoQ to $1.8M; adjusted gross margin 58%, up 190 bps QoQ; cash $112.1M, no debt.","Recurring revenue $4.8M, up 10% YoY, representing 35% of total Q3 revenue; FTIR portfolio momentum with XplorIR placements up 30% QoQ.","FY 2025 revenue guidance reiterated: $54-56M (13-17% growth); CEO expects positive adjusted EBITDA in Q4."],"consensus_eps_estimate":null,"consensus_eps_actual":0.43,"consensus_revenue_estimate":null,"consensus_revenue_actual":38817000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":331814522.81249994,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138334,"accession_number":"0001104659-25-073916","cik":1555279,"company_name":"908 Devices Inc.","ticker":"MASS","form_type":"8-K","filed_at":"2025-08-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"908 Devices Q2 revenue $13.0M (+14% YoY); raises 2025 revenue outlook to $54-56M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue from continuing ops $13.0M (+14% YoY); recurring revenue $4.7M (+28%, 36% of total).","Adjusted gross margin 56% (down 220 bps on warranty costs); net loss from cont. ops $12.9M vs $7.6M.","Full-year 2025 revenue guidance raised to $54-56M (from $53-55M), implying 13-17% growth.","Installed base grew 27% YoY to 3,336; record XplorIR placements; launched VipIR handheld analyzer.","Restructuring reduced sq footage 44% and headcount 39%; acquired KAF Manufacturing for $2.75M in July."],"consensus_eps_estimate":null,"consensus_eps_actual":0.85,"consensus_revenue_estimate":null,"consensus_revenue_actual":24813000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":331814522.81249994,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138333,"accession_number":"0001104659-25-073391","cik":1555279,"company_name":"908 Devices Inc.","ticker":"MASS","form_type":"8-K","filed_at":"2025-08-04T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"908 Devices appoints Dr. Brandi Vann to board; Jeff George resigns","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jeff George resigned from Board effective July 31, 2025; departure follows sale of bioprocessing portfolio.","Brandi Vann appointed to fill vacancy; former DoD Principal Deputy Assistant Secretary for Nuclear, Chemical, Biological Defense.","Dr. Vann receives $40k annual cash retainer and $200k initial equity award (50% RSUs, 50% NQSOs) vesting over 3 years.","Tony Hunt appointed as Compensation Committee Chair, replacing George.","Company refocuses on public health, safety and defense tech; Vann's expertise aligns with strategic shift."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":331814522.81249994,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155780,"accession_number":"0001104659-25-059685","cik":1555279,"company_name":"908 Devices Inc.","ticker":"MASS","form_type":"8-K","filed_at":"2025-06-16T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Board changes: Eisenberg resigns, co-founder Brown appointed director","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Marcia Eisenberg resigned from board and compensation committee effective June 12, 2025.","Eisenberg's resignation follows the company's sale of its bioprocessing product portfolio.","Co-founder Christopher D. Brown appointed to board as Class III director term expiring at 2026 annual meeting.","Brown is currently VP Analytics R&D at Repligen (RGEN), which purchased 908's bioprocessing portfolio.","Brown waived initial compensation under the non-employee director policy; continues consulting agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":331814522.81249994,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155779,"accession_number":"0001104659-25-059365","cik":1555279,"company_name":"908 Devices Inc.","ticker":"MASS","form_type":"8-K","filed_at":"2025-06-13T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"908 Devices stockholders re-elect three Class II directors and ratify auditor at annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Directors Kevin Knopp, Tony Hunt, and Mark Spoto re-elected with 17.1M–17.3M votes for each; broker non-votes of 6.5M.","Ratification of PricewaterhouseCoopers as auditor for FY 2025 approved: 25.1M for, 17,382 against, 167,643 abstain.","Meeting held June 12, 2025; quorum of 70.8% of outstanding shares (25.3M of 35.7M shares)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":331814522.81249994,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155778,"accession_number":"0001104659-25-047567","cik":1555279,"company_name":"908 Devices Inc.","ticker":"MASS","form_type":"8-K","filed_at":"2025-05-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"908 Devices Q1 revenue up 59% to $11.8M; reiterates FY25 outlook of $53-55M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue from continuing ops $11.8M (+59% YoY); handheld product & service revenue $11.0M (+86%).","Net loss from continuing ops $9.8M vs $5.9M YoY; adjusted EBITDA loss improved to $4.6M from $5.3M.","Recurring revenue $4.4M (+54% YoY), representing 37% of total revenue; installed base grew 28% to 3,172 devices.","Adjusted gross margin 54%, up ~75 bps YoY; GAAP gross margin 47% (down from 52%) due to international mix.","Cash and marketable securities $124.3M, no debt; reiterates FY25 revenue guidance of $53-55M."],"consensus_eps_estimate":null,"consensus_eps_actual":1.23,"consensus_revenue_estimate":null,"consensus_revenue_actual":11777000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":331814522.81249994,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":174253,"accession_number":"0001104659-25-021805","cik":1555279,"company_name":"908 Devices Inc.","ticker":"MASS","form_type":"8-K/A","filed_at":"2025-03-07T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"908 Devices completes sale of desktop business to Repligen; pro forma shows $40.4M net loss from continuing ops in 2024","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Sold desktop portfolio (Maverick, Rebel, Maven, Trace C2, ZipChip) to Repligen for ~$66M net upfront cash after transaction costs.","Estimated gain on sale of $54.7M treated as discontinued operations; pro forma net loss from continuing ops improved to $(40.4M) in 2024 from $(72.2M) historical.","Pro forma 2024 continuing ops revenue of $47.7M vs historical total $59.6M; loss per share from continuing ops $(1.19) vs historical $(2.12).","Transaction includes supply agreement and transition services; estimated bonus of $0.65M to remaining employees.","Cumulative translation adjustment of $1.1M released upon sale of 908 Devices GmbH."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":331814522.81249994,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":174255,"accession_number":"0001104659-25-020022","cik":1555279,"company_name":"908 Devices Inc.","ticker":"MASS","form_type":"8-K","filed_at":"2025-03-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"908 Devices Q4 revenue up 31% YoY; divests desktop business to Repligen for $70M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $18.8M (+31% YoY); full year $59.6M (+19% YoY); recurring revenue 39% of total.","Divested desktop portfolio (MAVEN, MAVERICK, REBEL, ZipChip) to Repligen for $70M (~6x multiple).","Adjusted gross margin improved to 55% for FY2024, up ~250 bps; expects mid-to-high 50% range in 2025.","Guides 2025 continuing ops revenue $53-55M (11-15% growth); expects Adj. EBITDA positivity by Q4 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":331814522.81249994,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":174254,"accession_number":"0001104659-25-020021","cik":1555279,"company_name":"908 Devices Inc.","ticker":"MASS","form_type":"8-K","filed_at":"2025-03-04T23:59:59+00:00","items":["1.01","2.01","8.01","9.01"],"status":"ready","headline":"908 Devices sells desktop bioprocessing PAT portfolio to Repligen for $70M cash","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Purchase price $70M in cash, subject to customary working capital adjustment and escrow for indemnification.","Products sold: MAVERICK, MAVEN, REBEL, ZipChip; 908 Devices retains handheld device business.","Company agrees to 5-year non-compete in bioprocessing PAT and 18-month employee non-solicit.","Transition services provided through Dec 2025; supply and IP license agreements also executed.","Disposition does not require stockholder approval as it is not substantially all assets; pro forma financials to follow."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":331814522.81249994,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":191182,"accession_number":"0001104659-24-116339","cik":1555279,"company_name":"908 Devices Inc.","ticker":"MASS","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"908 Devices reports Q3 revenue up 17% to $16.8M, net loss $29.3M, announces 11% layoffs and manufacturing relocation","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Revenue increased 17% year over year to $16.8 million, driven by handheld product sales.","Net loss of $29.3 million includes a $30.5 million goodwill impairment charge.","Announced 11% workforce reduction, expects annual cost savings of approximately $4.2 million starting in 2025.","Manufacturing transition from Boston to Morrisville, NC and Danbury, CT expected to generate $2.4 million annual savings from 2026.","2024 revenue guidance updated to $56-$58 million, reflecting 11%-15% growth over 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":331814522.81249994,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":207662,"accession_number":"0001104659-24-095714","cik":1555279,"company_name":"908 Devices Inc.","ticker":"MASS","form_type":"8-K","filed_at":"2024-08-30T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"908 Devices posts updated investor presentation on website","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Updated Investor Presentation posted to ir.908devices.com on August 30, 2024.","Management will use the presentation in meetings with investors, analysts, and other parties.","Presentation may be updated periodically; company encourages investors to review it."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":331814522.81249994,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":207661,"accession_number":"0001104659-24-086090","cik":1555279,"company_name":"908 Devices Inc.","ticker":"MASS","form_type":"8-K","filed_at":"2024-08-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Q2 revenue up 16% to $14M, net loss widens to $12.5M; reiterates FY24 guidance $63-65M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $14.0M (+16% YoY); handheld devices up 26% to $11.1M, desktop down 9% to $2.9M.","Net loss $12.5M vs $9.3M prior year; adjusted EBITDA loss $7.3M vs $7.7M.","Gross margin 53% (+490 bps YoY); adjusted gross margin 58% (+800 bps).","Installed base grew to 3,067 devices; recurring revenue 38% of total, up 33% YoY.","Reiterated full-year 2024 revenue guidance $63M-$65M (25-29% growth) includes $11M from RedWave."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.7,"consensus_revenue_estimate":null,"consensus_revenue_actual":24038000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":331814522.81249994,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":207660,"accession_number":"0001104659-24-078571","cik":1555279,"company_name":"908 Devices Inc.","ticker":"MASS","form_type":"8-K/A","filed_at":"2024-07-09T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"908 Devices files RedWave financials; acquired firm had $13.8M revenue, $2.1M net income in 2023","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Acquisition of RedWave (CAM2 Technologies) closed April 29, 2024; now a wholly-owned subsidiary of 908 Devices.","RedWave FY2023 audited: total revenue $13.75M, net income $2.14M, gross profit $7.26M.","RedWave total assets $7.38M, members' equity $2.10M as of Dec 31, 2023.","Two customers represented 39% of 2023 revenue; two customers accounted for 85% of accounts receivable at year-end.","Pro forma combined financials for FY2023 and Q1 2024 filed as Exhibit 99.4."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":331814522.81249994,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":225127,"accession_number":"0001104659-24-074581","cik":1555279,"company_name":"908 Devices Inc.","ticker":"MASS","form_type":"8-K","filed_at":"2024-06-25T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"908 Devices appoints former DEA Administrator Michele Leonhart to Board of Directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Michele Leonhart joined Board as Class I director on June 25, 2024; term expires at 2027 annual meeting.","Former DEA Administrator with 34 years of experience, including leading $2.4B agency with 227 domestic and 86 foreign offices.","Compensation: $40,000 annual cash retainer, initial $200K equity (50% RSUs/50% NQSOs) vesting over 3 years.","CEO Kevin Knopp cites recent RedWave Technology acquisition and Leonhart's forensics expertise to boost market penetration.","Board expands from 8 to 9 members; no arrangements or transactions requiring disclosure under Item 404(a)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":331814522.81249994,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":225126,"accession_number":"0001104659-24-071736","cik":1555279,"company_name":"908 Devices Inc.","ticker":"MASS","form_type":"8-K","filed_at":"2024-06-14T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"908 Devices shareholders elect two Class I directors, ratify PwC as auditor","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Fenel M. Eloi elected with 18,885,971 For, 4,548,553 Withheld, 6,047,784 broker non-votes.","Jeffrey P. George elected with 18,790,032 For, 4,644,492 Withheld, same broker non-votes.","Ratification of PricewaterhouseCoopers LLP as auditor passed with 29,470,794 For, 8,393 Against, 3,121 Abstain.","Quorum of 89.4% achieved with 29,482,308 shares represented out of 32,983,276 outstanding."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":331814522.81249994,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":225125,"accession_number":"0001104659-24-054511","cik":1555279,"company_name":"908 Devices Inc.","ticker":"MASS","form_type":"8-K","filed_at":"2024-04-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"908 Devices Q1 revenue $10.0M (+5% YoY); acquires RedWave for $45M; FY24 guidance $63-65M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $10.0M (+5% YoY); handheld devices $7.4M (+20%), desktop $2.6M (-18%).","Net loss $10.9M ($0.33 per share), improved from $12.5M loss in Q1 2023.","Cash, equivalents & marketable securities $134.2M; zero debt; used $45M cash for RedWave acquisition.","Acquired RedWave Technology post-quarter-end, adding complementary forensics products and $11M expected FY24 revenue.","FY2024 revenue guidance raised to $63-65M (25-29% growth vs 2023), including 8 months of RedWave contribution."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.33,"consensus_revenue_estimate":null,"consensus_revenue_actual":9991000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":331814522.81249994,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":225124,"accession_number":"0001104659-24-054505","cik":1555279,"company_name":"908 Devices Inc.","ticker":"MASS","form_type":"8-K","filed_at":"2024-04-30T23:59:59+00:00","items":["1.01","2.01","3.02","7.01","9.01"],"status":"ready","headline":"908 Devices acquires RedWave Technology for $53.5M in cash and stock; expands forensics portfolio","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Initial consideration: $45M cash + 1.5M shares ($8.5M); total $53.5M. Up to 4M earnout shares (≈$22.7M) if revenue hits $37M-$45M over 2 years.","RedWave 2023 unaudited: revenue $13.7M (+20%+ YoY), gross margin 52%, operating margin 15%. Expected to add $11M to 2024 revenue (8 months).","RedWave provides portable FTIR analyzers; complements 908 Devices' mass spec devices for forensics, industrial QC and PAT applications.","Acquisition closed April 29, 2024; RedWave becomes wholly-owned subsidiary. Sellers subject to 180-day lock-up on closing shares.","RedWave employs 39, has placed >700 analyzers in >20 countries; CEO Jon Frattaroli joins as VP, Strategy at 908 Devices."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":331814522.81249994,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":244350,"accession_number":"0001104659-24-030757","cik":1555279,"company_name":"908 Devices Inc.","ticker":"MASS","form_type":"8-K","filed_at":"2024-03-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Q4 revenue $14.4M (+23% YoY); net loss $7.4M; FY 2024 guidance $52-54M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $14.4M, up 23% YoY; handheld revenue +57% in Q4.","FY 2023 revenue $50.2M (+7% YoY); handheld revenue +28% YoY.","Net loss $7.4M in Q4 ($0.23/shr) vs $9.8M ($0.31/shr) prior year.","FY 2024 revenue guidance $52-54M (4-8% growth), cash $145.7M, no debt.","Recurring revenue 33% of product and service revenues; installed base 2,853 devices."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":331814522.81249994,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":261773,"accession_number":"0001104659-23-115003","cik":1555279,"company_name":"908 Devices Inc.","ticker":"MASS","form_type":"8-K","filed_at":"2023-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"908 Devices Q3 revenue $14.3M (-9% YoY), net loss $7.1M; narrows 2023 outlook","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $14.3M in Q3 2023 vs $15.7M in Q3 2022; handheld $11.7M, desktop $2.5M, recurring $3.6M.","Net loss $7.1M ($0.22 loss per share) vs $6.3M ($0.20) a year ago.","Gross margin 55% vs 59% on lower revenue and higher service costs.","Cash $148M with no debt; down $5M from prior quarter.","FY 2023 revenue guidance narrowed to $49-51M (prior $49-52M), implying 4-9% growth."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.9,"consensus_revenue_estimate":null,"consensus_revenue_actual":35878000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":331814522.81249994,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":278964,"accession_number":"0001104659-23-088592","cik":1555279,"company_name":"908 Devices Inc.","ticker":"MASS","form_type":"8-K","filed_at":"2023-08-08T23:59:59+00:00","items":["1.01","2.02","2.03","9.01"],"status":"ready","headline":"908 Devices Q2 revenue up 9% to $12.1M; raises FY2023 guidance low end","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 revenue $12.1M (+9% YoY); handheld rev $8.8M (+27%); recurring rev $4.0M (+39%).","Net loss $9.3M ($0.29/sh) vs $8.1M prior yr; gross margin 48% vs 60%; cash $153M, no debt.","FY2023 revenue guidance updated to $49M-$52M (4-11% growth), raising low end from $48M.","Entered $10M revolving credit facility with SVB; asset-backed, requires $20M deposit; no borrowings outstanding."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.68,"consensus_revenue_estimate":null,"consensus_revenue_actual":21581000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":331814522.81249994,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":297277,"accession_number":"0001104659-23-072223","cik":1555279,"company_name":"908 Devices Inc.","ticker":"MASS","form_type":"8-K","filed_at":"2023-06-16T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"908 Devices stockholder meeting re-elects directors, ratifies auditor","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Class III directors Crandell, Eisenberg, Hrusovsky re-elected; Crandell received 18.5M for, 7.7M withheld.","Eisenberg received 22.3M for, 3.9M withheld; Hrusovsky 19.3M for, 6.9M withheld.","Ratification of PwC as auditor for FY 2023: 30.2M for, 8,279 against, 17,323 abstain.","Approximately 30.2M shares voted, representing 94.17% of outstanding shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":331814522.81249994,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":297276,"accession_number":"0001104659-23-057470","cik":1555279,"company_name":"908 Devices Inc.","ticker":"MASS","form_type":"8-K","filed_at":"2023-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"908 Devices Q1 revenue up 14% to $9.5M; net loss widens to $12.5M; reiterates FY23 outlook","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $9.5M (+14% YoY); recurring revenue $4.2M (+67%); handheld up 38%, desktop down 13%.","Net loss $12.5M ($0.39/share) vs $9.4M ($0.30) YoY; gross margin 46% vs 50%.","Ended Q1 with $161M cash, no debt after paying down $15M debt.","Reiterated FY23 revenue guidance $48M-$52M (2%-11% growth).","Installed base 2,468 devices; 78 placements; new NATO purchasing vehicle for MX908."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.39,"consensus_revenue_estimate":null,"consensus_revenue_actual":9487000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":331814522.81249994,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":317639,"accession_number":"0001104659-23-029296","cik":1555279,"company_name":"908 Devices Inc.","ticker":"MASS","form_type":"8-K","filed_at":"2023-03-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"908 Devices reports Q4 2022 revenue down 27% YoY to $11.6M; guides FY2023 rev $48-52M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY2022 revenue $46.9M (+11% YoY); recurring revenue up 101% to $15.7M, representing 1/3 of total.","Q4 2022 revenue $11.6M (-27% YoY) due to timing of $8M U.S. Army MX908 shipment in Q4 2021.","Net loss widened: Q4 loss $9.8M ($0.31/share) vs $3.5M ($0.12/share) in Q4 2021; FY2022 net loss $33.6M.","Cash and equivalents $188M; debt $15M; cash consumed $36M in 2022 including $14M for acquisition.","FY2023 revenue guidance $48-52M (2-11% growth); launched MAVEN on-line device for bioprocessing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":331814522.81249994,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":335874,"accession_number":"0001104659-22-117687","cik":1555279,"company_name":"908 Devices Inc.","ticker":"MASS","form_type":"8-K","filed_at":"2022-11-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"908 Devices Q3 revenue up 26% to $15.8M, guides FY2022 revenue $46M-$49M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $15.8M (+26% YoY); gross margin 59% vs 54%.","Net loss $6.3M ($0.20/share) vs $5.2M ($0.19) prior year.","FY2022 revenue guidance lowered to $46M-$49M (midpoint $47.5M, ~13% YoY growth).","Cash $193.7M, debt $15M; installed base 2,317 devices (175 placed in Q3).","Executed TRACE Analytics acquisition; received $3.1M U.S. Army order."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.76,"consensus_revenue_estimate":null,"consensus_revenue_actual":35209000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":331814522.81249994,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":335873,"accession_number":"0001104659-22-115727","cik":1555279,"company_name":"908 Devices Inc.","ticker":"MASS","form_type":"8-K","filed_at":"2022-11-08T23:59:59+00:00","items":["1.01","1.02","2.03","9.01"],"status":"ready","headline":"908 Devices replaces $25M SVB credit line with $35M Silicon Valley Bank facility, maturing Nov 2025","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["New $35M revolving credit line with Silicon Valley Bank; replaces prior $25M Signature Bank facility.","Interest rate: greater of 3.50% or Prime Rate minus 0.50%; floating; no amounts outstanding at signing.","Line matures Nov 2, 2025; secured by substantially all assets (IP negative pledge).","Financial covenant: minimum unrestricted cash minus advances >= $10M or 9 months cash burn.","Prior facility terminated voluntarily with no early termination penalties; no prepayment penalty if replaced by Bank."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":331814522.81249994,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":353284,"accession_number":"0001104659-22-087594","cik":1555279,"company_name":"908 Devices Inc.","ticker":"MASS","form_type":"8-K","filed_at":"2022-08-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"908 Devices reports Q2 revenue $11.1M (+34% YoY), reiterates FY22 guidance; acquires TRACE Analytics","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 revenue $11.1M, up 34% YoY; gross margin 60% vs 53% prior year.","Net loss $8.1M ($0.26 loss per share) vs $7.4M ($0.27) prior year.","Installed base 2,142 devices; placed 124 devices in Q2.","FY2022 revenue guidance reaffirmed at $52M-$55M (23%-30% growth).","Acquired TRACE Analytics, an online bioreactor sampling and biosensor technology provider."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.56,"consensus_revenue_estimate":null,"consensus_revenue_actual":19412000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":331814522.81249994,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":371006,"accession_number":"0001104659-22-072388","cik":1555279,"company_name":"908 Devices Inc.","ticker":"MASS","form_type":"8-K","filed_at":"2022-06-17T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"908 Devices reports 2022 annual meeting vote results; all directors elected, auditor ratified","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All three Class II director nominees elected (Knopp: 20.5M for, 4.0M withheld; Hunt: 24.1M for, 0.4M withheld; Spoto: 16.3M for, 8.2M withheld).","Ratification of PricewaterhouseCoopers as independent auditor for FY2022 passed: 29.3M for, 17,334 against, 34,035 abstain.","Quorum achieved with 29,325,724 shares (93.44% of outstanding) present or represented at the meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":331814522.81249994,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":371005,"accession_number":"0001104659-22-057927","cik":1555279,"company_name":"908 Devices Inc.","ticker":"MASS","form_type":"8-K","filed_at":"2022-05-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"908 Devices Q1 revenue up 50% to $8.3M; reiterates FY22 guidance $52-55M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $8.3M (+50% YoY); net loss $9.4M ($0.30/share) vs $6.1M ($0.22) last year.","Desktop revenue +68% YoY; installed base 2,018 devices with 83 placed in Q1.","Gross margin 50% (down from 52%) on investments; op. expenses $13.7M vs $8.7M.","Cash & equiv. $223M, debt ~$15M; reiterates FY22 rev. outlook $52-55M (23-30% growth).","MX908 updates (iOS Bluetooth, robot interface); CPI partnership for bioprocessing."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.3,"consensus_revenue_estimate":null,"consensus_revenue_actual":8306000.0,"consensus_period":"2022-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":331814522.81249994,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":371004,"accession_number":"0001104659-22-044640","cik":1555279,"company_name":"908 Devices Inc.","ticker":"MASS","form_type":"8-K","filed_at":"2022-04-11T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Nicolas Barthelemy not to stand for re-election at June 2022 annual meeting","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Nicolas Barthelemy will not stand for re-election to board at June 2022 Annual Meeting; serves until then as director and Compensation Committee chair.","Departure is not due to any disagreement with management regarding operations, policies, or practices.","Board expects Jeffrey P. George to become Compensation Committee chair and Marcia Eisenberg, Ph.D. to join the committee from the Annual Meeting date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":331814522.81249994,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":390023,"accession_number":"0001104659-22-031039","cik":1555279,"company_name":"908 Devices Inc.","ticker":"MASS","form_type":"8-K","filed_at":"2022-03-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"908 Devices Q4 rev $15.8M (+177% YoY); net loss $3.5M; FY22 guide $52-55M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Full-year 2021 revenue $42.2M (+57% YoY); net loss $22.2M ($0.79 loss per share).","Q4 gross margin improved to 58% from 49%; installed base expanded to 1,935 devices.","Cash $224M at year-end; debt outstanding $15M.","FY 2022 revenue outlook $52M-$55M, representing 23%-30% growth over FY 2021.","Commercial traction with all top 20 biopharma; Tony Hunt (Repligen CEO) added to board."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":331814522.81249994,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":390022,"accession_number":"0001104659-22-029353","cik":1555279,"company_name":"908 Devices Inc.","ticker":"MASS","form_type":"8-K","filed_at":"2022-03-02T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"908 Devices appoints Repligen CEO Tony J. Hunt to Board, effective March 2, 2022","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Tony J. Hunt, President and CEO of Repligen (RGEN), appointed to Board expanding from 8 to 9 directors.","Class II director with term expiring at June 2022 annual meeting; receives $40K annual cash retainer.","One-time initial equity award of $200K (50% RSUs, 50% NQSOs) vesting over three years.","Also eligible for future annual equity awards of $135K on same terms as other non-employee directors.","Hunt brings over 20 years bioprocessing experience; previously President of Bioproduction at Life Technologies."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":331814522.81249994,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":390021,"accession_number":"0001104659-22-002487","cik":1555279,"company_name":"908 Devices Inc.","ticker":"MASS","form_type":"8-K","filed_at":"2022-01-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"908 Devices pre-announces Q4 revenue ≥$15.1M (+165% YoY); FY21 ≥$41.5M (+54% YoY)","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Preliminary Q4 2021 revenue at least $15.1M, up from $5.7M in Q4 2020 (+165%).","Preliminary full-year 2021 revenue at least $41.5M, up from $26.9M in 2020 (+54%).","CEO cites strong commercial execution and sequential growth in desktop device placements.","Full Q4 and FY 2021 results to be announced in early March 2022; figures subject to audit."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.79,"consensus_revenue_estimate":null,"consensus_revenue_actual":42206000.0,"consensus_period":"2021-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":331814522.81249994,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":408007,"accession_number":"0001104659-21-134026","cik":1555279,"company_name":"908 Devices Inc.","ticker":"MASS","form_type":"8-K","filed_at":"2021-11-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"908 Devices Q3 revenue $12.5M (+107% YoY), net loss $5.2M; narrows FY guidance to $41-43M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 revenue $12.5M, up 52% sequentially and 107% YoY; net loss $5.2M ($0.19 loss per share).","Product/service gross margin 54% vs 64% a year ago; operating expenses rose to $12.1M from $5.1M.","Installed base reached 1,714 devices with 184 placements in Q3, driven by handheld adoption.","Full year 2021 revenue guidance raised low end to $41-43M from $40-43M, growth 52-60%.","Cash $139M; $15M debt; launched ZipChip Oligonucleotides kit, partnered with Ohio AG for counterfeit drug detection."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.68,"consensus_revenue_estimate":null,"consensus_revenue_actual":26365000.0,"consensus_period":"2021-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":331814522.81249994,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":427005,"accession_number":"0001104659-21-099784","cik":1555279,"company_name":"908 Devices Inc.","ticker":"MASS","form_type":"8-K","filed_at":"2021-08-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"908 Devices Q2 revenue $8.3M; raises 2021 revenue outlook to $40-43M (49-60% YoY growth)","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $8.3M, up 49% from Q1 2021 and down 26% from $11.1M in Q2 2020 on a one-time prior-year shipment.","Desktop revenue grew 70% YoY and contributed one-third of total Q2 2021 revenue.","Net loss $7.4M ($0.27 per share) vs net income $2.1M ($0.11) in Q2 2020.","FY 2021 revenue guidance raised to $40-43M from prior $38-40M, implying 49-60% annual growth.","Cash $141M; debt $15M; installed base reached 1,530 devices with 103 placements in Q2."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.49,"consensus_revenue_estimate":null,"consensus_revenue_actual":13820000.0,"consensus_period":"2021-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":331814522.81249994,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}